{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "TOI",
  "name": "The Oncology Institute, Inc.",
  "url": "https://orbyd.app/dossiers/TOI/",
  "json_url": "https://orbyd.app/dossiers/TOI.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Debt refi (2026-07-09: $86M Deerfield convert → $75M OrbiMed term loan to 2031, no equity) removed the 2027 maturity wall and triggered a sell-side cluster — Lake Street initiate $10 (7/06), BTIG $8→$9 (7/09), consensus $8.40. But a 24x call-volume spike took it to a $6.67 high and it round-tripped 20% to $5.35 in three sessions. Narrative accelerating, structure failed. Aug 12 Q2 print is the gate.",
  "invalidation_trigger": "A daily close below $4.90 (forfeits the rising 50-day and erases all price progress from the July refinancing/upgrade cluster). Secondarily, the 2026-08-12 Q2 print cutting FY26 adjusted-EBITDA guidance below the $0 breakeven floor, pulling the $5–15M FCF guide negative on OrbiMed interest expense, or a sequential decline in capitation revenue.",
  "catalyst_date": "2026-08-12",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Analyst cluster July 2026: Lake Street initiates Buy PT $10 (7/06); BTIG raises $8->$9 Buy (7/09); B. Riley $8; Needham $7 (6/17). Consensus ~$8.40, 5 buy / 1 sell (Weiss maintains sell).",
    "Insider pattern: 10% owner Jorey Chernett has bought FOUR open-market tranches into rising prices — 33,500 @ $4.07 (5/20), 12,000 @ $4.75 (6/05), 18,000 @ $5.02 (6/23), 15,000 @ ~$5.85 (7/10). Counterweight: CMO Yale Podnos sold 23,451 @ $5.38 (6/08) under a 10b5-1 plan.",
    "FLOW WARNING 2026-07-09: 25,717 call contracts vs 1,030 average = +2,397%. Failed breakout / distribution signature — retail flow has already arrived.",
    "Key levels: pre-news shelf $5.30-5.35 (must hold for the July spike to become a base); 50-day ~$4.90; 200-day ~$3.78. Constructive reversal = higher low above $5.30 then reclaim of $6.11 on expanding volume.",
    "Squeeze mechanics live: short float ~11%, cover ratio ~3.5d, float ~57.7M of 99.98M shares out, ~$10M avg daily $-volume. Sizing is the binding constraint, not conviction — probe at 1-2% max.",
    "Fundamentals: Q1'26 rev $147.4M (+41.2% YoY) beat ~$143.2M guide; net loss $2.5M vs $19.6M YoY. FY26 guide rev $630-650M, adj-EBITDA $0-9M (first profitable year as public co). Full delegated economics not until 2027. Florida capitation scaling toward ~200k MA lives across 25 counties from Q3'26.",
    "Rate sensitivity is now DIRECT: $75M floating at SOFR+5.75% feeds front-end rate moves straight into interest expense against a thin EBITDA base. New risk factor vs the old fixed convertible.",
    "Cybersecurity overhang: Nov 2025 incident; 2026-05-22 follow-up confirmed a software vendor had unauthorized access to information. Still no remediation-cost disclosure — watch the 8/12 print."
  ],
  "body_markdown": "\nalready researched\n\n## TOI — The Oncology Institute, Inc.\n\n## Current Thesis\n\nThe Oncology Institute runs value-based community oncology — capitated and delegated-risk contracts with Medicare Advantage payers, plus a dispensary/specialty-pharmacy segment — and is inflecting to its first full year of profitability after years of fee-for-service losses. Since the last read the story has changed in kind, not just degree. On 2026-07-09 the company refinanced its $86M Deerfield senior secured convertible note with a $75M OrbiMed term loan maturing 2031 plus ~$11M of balance-sheet cash, retiring the convertible without issuing equity and pushing the maturity wall out from August 2027 by nearly four years. Sell-side responded inside a single week: Lake Street initiated Buy with a $10 target on 2026-07-06, BTIG lifted $8 → $9 on 2026-07-09, and consensus now sits near $8.40 against a $5.35 close (2026-07-17).\n\nWhat complicates a fresh entry is the tape's reaction to that news. Call volume on 2026-07-09 hit 25,717 contracts against a 1,030 average — roughly 24x normal — price ran to a $6.67 fifty-two-week high by 2026-07-14, then gave back about 20% in three sessions to $5.35. The narrative is accelerating; the price structure just printed a failed breakout on top of a retail-flow blowout. Those are different clocks, and only one of them is favourable right now.\n\n## Bull Case\n\n- **Convertible overhang eliminated without dilution (2026-07-09).** The $86M Deerfield convert is gone, replaced by a $75M OrbiMed term loan at the higher of 3% or SOFR+5.75%, maturing 2031-07-01. No equity issued. For a $535M-cap name that had a 2027 maturity wall, this removes both the refinancing risk and the conversion-dilution ceiling that capped the multiple.\n- **Insider buying is now a four-tranche pattern paid up into strength.** 10% owner Jorey Chernett: 33,500 sh @ $4.07 (2026-05-20), 12,000 @ $4.75 (2026-06-05), 18,000 @ $5.02 (2026-06-23), and 15,000 @ ~$5.85 (2026-07-10, $87,750), taking him to 10,630,858 shares. An insider lifting his bid four times across a 44% price advance is the cleanest signal on this tape.\n- **Coverage is broadening, not just re-rating.** Lake Street's 2026-07-06 initiation frames the setup on payer economics: Medicare Part D spending on oral oncolytics went from under $5B in 2013 to $32B in 2024, with total oncology drug spend projected at $180B in 2028 versus $99B in 2023. Rising drug cost pressures insurer margins, which is precisely what makes a delegated-risk oncology operator worth paying for.\n- **Fundamental trajectory intact.** Q1'26 revenue $147.4M (+41.2% YoY) beat the ~$143.2M guide; net loss narrowed to $2.5M from $19.6M YoY. FY26 guidance of $630–650M revenue and $0–9M adjusted EBITDA would be the first profitable year as a public company. BTIG expects positive adjusted EBITDA and free cash flow in 2H'26.\n- **Structural ramp still ahead.** Florida delegated capitation is guided toward ~200,000 Medicare Advantage lives across 25 counties beginning Q3'26, with a provider portal launched to the full non-employed Florida network. Full delegated-contract economics do not land until 2027, so the operating leverage is in front of the print rather than behind it.\n- **Trend still intact on the higher timeframe.** Price holds well above the 50-day near $4.90 and the 200-day near $3.78. The 200-day has been rising all year.\n\n## Bear Case\n\n- **The breakout failed.** $6.67 on 2026-07-14, then $5.935 (-5.5%) on 2026-07-15 and $5.35 by 2026-07-17 — roughly 20% surrendered in three sessions on collapsing volume. A high made on 24x call volume and immediately rejected is the distribution signature, and buying the retest of a failed high is how micro-cap momentum books bleed.\n- **Refinancing traded dilution risk for cash-interest risk.** SOFR+5.75% on $75M is high-single-digit millions of annual cash interest against a FY26 adjusted-EBITDA guide whose *low end is zero*. The $5–15M free-cash-flow guide was set before that coupon existed. If the Q2 print does not raise the EBITDA floor, the debt service consumes the entire inflection.\n- **Cash cushion is thinner than the headline.** Cash was $30.3M at 2026-03-31; roughly $11M went into the refinancing. Pro-forma liquidity in the high teens for a company running $630M+ of annualized revenue leaves very little room for a delegated contract that ramps slowly or a working-capital swing in the dispensary segment.\n- **Retail flow has already arrived.** A 2,397% single-day call-volume spike is not early positioning — it is the narrative going public. Combined with 11%+ short float, the July leg had more to do with gamma and covering than with an incremental fundamental datapoint.\n- **Price is stretched against its own base.** $5.35 sits roughly 42% above the 200-day and 9% above the 50-day, after a move from a $2.32 fifty-two-week low. Mean reversion in a $535M-cap name with ~1.9M average daily shares is fast and unforgiving.\n- **Insider selling exists on the other side.** CMO Yale Podnos sold 23,451 shares @ $5.38 on 2026-06-08. Pre-arranged under a trading plan, so it carries less signal than the buys, but it is not nothing at these levels.\n- **A \"sell\" rating persists.** Weiss Ratings maintains sell against five buys — consensus is bullish but not unanimous, and the $8.40 average target embeds the 2027 delegated economics arriving on schedule.\n\n## Setup & Price Structure\n\nSpot $5.35 (2026-07-17 close, +1.71% on the day). Fifty-two-week range $2.32–$6.67. Market cap ~$535M on 99.98M shares outstanding, float roughly 57.7M with short interest around 11% — the squeeze mechanics that amplified the July move are still loaded.\n\nThe structure to watch is the July gap-and-fail. Price consolidated near $5.30–5.35 before the 2026-07-09 refinancing news, spiked to $6.67 in three sessions, and has now round-tripped the entire move back to the pre-news shelf. That shelf is the line that matters: holding $5.30 and building a higher low turns the July spike into a base, while losing it puts the 50-day near $4.90 in play immediately. Below $4.90 the whole July catalyst sequence — refi, two target raises, the insider buy at $5.85 — will have produced no net price progress, which would say the news was already discounted.\n\nVolume tells the same story from the other side. Sellers are not aggressive; buyers have simply stepped away after the flow event cleared. That is a name that needs time and a fresh catalyst rather than an immediate re-entry, and the fresh catalyst has a date on it.\n\nSizing discipline applies regardless of view: ~$10M of average daily dollar volume means position construction, not conviction, is the binding constraint here. This is probe territory at 1–2%.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-12 — Q2'26 earnings release and call (confirmed).** The binary. Watch three lines: whether FY26 adjusted-EBITDA guidance holds or lifts off the $0 floor, whether the free-cash-flow guide of $5–15M survives the new OrbiMed coupon, and sequential capitation revenue. Avoid fresh entries inside the three trading days before the print.\n- **Q3'26 (undated, ~2026-08-01 onward) — Florida delegated capitation scaling toward ~200,000 Medicare Advantage lives across 25 counties.** No fixed announcement date; expect it quantified on the 2026-08-12 call rather than as a standalone release.\n- **Ongoing — Form 4 filings from the 10% owner.** A fifth open-market tranche above $5.85 would confirm the July buy was not a one-off top-tick; a stop in the pattern after four consecutive buys is itself information.\n- **No PDUFA, FDA, or regulatory dates.** This is a services operator, not a drug developer — there is no binary approval event in the window.\n\n## What Would Change Our Mind\n\nThe thesis breaks on a daily close below $4.90, which forfeits the rising 50-day and erases every point of price progress the July catalyst cluster produced. And a narrative that cannot hold its gains on good news is a narrative that has already been paid for.\n\nSecondarily, the 2026-08-12 print is a hard gate. FY26 adjusted-EBITDA guidance cut below the $0 breakeven floor, a free-cash-flow guide pulled negative once the OrbiMed interest expense is modelled in full, or a sequential decline in capitation revenue would each independently end the profitability-inflection story that supports a $8.40 consensus target.\n\nThe constructive reversal is equally specific: a higher low above $5.30 followed by a reclaim of $6.11 on expanding volume would turn the July spike into a base rather than a blow-off, and would justify treating the failed breakout as a shakeout.\n\n## Correlation Notes\n\n- **Theme: health-managed-care, currently MATURING rather than accelerating.** The July move was company-specific — a balance-sheet event plus sell-side discovery — not a sector bid. Managed-care peers are not confirming with synchronized breakouts, which removes the cluster support that would otherwise justify chasing strength.\n- **Payer-margin sensitivity cuts both ways.** The Lake Street thesis rests on oncology drug inflation pressuring insurer margins and pushing volume toward delegated-risk operators. The same inflation is the cost line inside TOI's own capitated contracts. Medicare Advantage rate-notice headlines and MA utilization commentary from the large payers are the read-through to watch.\n- **Rate sensitivity is now direct.** With $75M floating at SOFR+5.75%, front-end rate moves feed straight into interest expense against a thin EBITDA base. A hawkish repricing is a fundamental headwind here in a way it was not under the fixed convertible.\n- **Micro-cap beta and squeeze correlation.** Short float above 11% with roughly a 3.5-day cover ratio means TOI trades with small-cap risk appetite as much as with healthcare services. Expect it to overshoot in both directions relative to sector moves.\n- **Not a biotech.** Recurring correction worth restating: this is a community-oncology services operator on capitated and delegated risk, not a drug developer. It does not correlate with XBI or clinical-readout cycles, and screening it against biotech comps produces the wrong risk model.",
  "first_seen": "2026-05-24",
  "last_analyzed": "2026-07-19T11:51:50+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}